H. Lawrence Remmel is Director at ATOSSA THERAPEUTICS, INC. (ATOS). They have made 5 open-market trades across 1 company since 2013, most recently 2026-05-12.
CIK 0001551817
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $33K since 2013, never a sale. Across 5 scored buys the stock is up 5.6% at ninety days, and 1.9 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ATOS | 10,683 | $31K |
Shares reported on the most recent Form 4, priced at the 2026-05-14 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 80% | 60% |
| Avg Move | -9.5% | +6.3% | +5.6% |
| Alpha | -7.7% | +5.9% | +1.9% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATOS | BUY | 2025-03-26 | 2025-03-28 | $0.70 | $7K | -8.8% | +9.2% | +29.0% |
| ATOS | BUY | 2017-04-17 | 2017-04-18 | $0.63 | $2K | -7.3% | -18.1% | -34.4% |
| ATOS | BUY | 2016-04-01 | 2016-04-04 | $0.33 | $495 | -0.0% | +0.3% | -6.7% |
| ATOS | BUY | 2015-06-12 | 2015-06-15 | $1.30 | $7K | -15.6% | +20.0% | +20.0% |
| ATOS | BUY | 2013-01-08 | 2013-01-09 | $4.12 | $16K | -15.6% | +20.0% | +20.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.